Elamipretide (Forzinity): Uses, Action, Evidence

Overview

Patients and caregivers dealing with Barth syndrome often ask whether any treatment can help with muscle weakness. Elamipretide, marketed as Forzinity, is the first therapy approved specifically to address this symptom.

Key takeaways

• Elamipretide is FDA-approved under the brand name Forzinity for improving muscle strength in Barth syndrome.
• It works by binding cardiolipin in the inner mitochondrial membrane, supporting mitochondrial structure and function.
• Approval covers adult and pediatric patients weighing at least 30 kg and was granted through the accelerated approval pathway.
• Continued approval depends on a confirmatory trial verifying clinical benefit beyond the muscle strength measure used so far.
• More than 20 clinical trials have registered work on this compound, spanning several conditions beyond Barth syndrome.

What elamipretide is

Elamipretide is classified as a mitochondrial cardiolipin binder. It localizes to the inner mitochondrial membrane, where it helps preserve normal mitochondrial shape and function. Because many cells rely on healthy mitochondria for energy production, this mechanism is the basis for its effect on muscle strength.

What elamipretide is approved for

Forzinity is approved to improve muscle strength in adult and pediatric patients with Barth syndrome who weigh at least 30 kg. The approval relies on accelerated approval, based on improvement in knee extensor muscle strength, an intermediate clinical endpoint rather than a direct measure of long-term benefit. Continued marketing may depend on a confirmatory trial that verifies clinical benefit. No boxed warning appears on the label.

What the evidence shows

Elamipretide has been studied in at least 21 registered clinical trials. A completed phase 2 trial examined a topical ophthalmic formulation for Leber's hereditary optic neuropathy, and a separate completed phase 2 trial looked at its impact on skeletal muscle function in elderly adults. An expanded access protocol has also made the compound available outside of standard trial enrollment. Together these studies reflect investigation across multiple conditions involving mitochondrial or muscle function, though the Barth syndrome indication is the only one with current approval.